
Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 40, 31, 3, 2, 19, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 9 and 1 molecules, respectively.
Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directβs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 40, 31, 3, 2, 19, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 9 and 1 molecules, respectively.
Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directβs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and itβs most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
331 Pages
- Introduction
- Global Markets Direct Report Coverage
- Nasopharyngeal Cancer β Overview
- Nasopharyngeal Cancer β Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Nasopharyngeal Cancer β Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nasopharyngeal Cancer β Companies Involved in Therapeutics Development
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- Akeso Inc
- Alphamab Oncology
- Ambrx Biopharma Inc
- Amgen Inc
- Apollomics Inc
- Ascentage Pharma Group International
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- AVEO Pharmaceuticals Inc
- BeiGene Ltd
- Biomics Biotechnologies Co Ltd
- BioSyngen Pte Ltd
- BP InnoMed Ltd
- Bristol-Myers Squibb Co
- Chengdu Wonho Biology Engineering Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- China Immunotech Co Ltd
- Compugen Ltd
- Eli Lilly and Co
- EpimAb Biotherapeutics Inc
- Eutilex Co Ltd
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Geneius Biotechnology Inc
- GenFleet Therapeutics (Shanghai) Inc
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- GeoVax Labs Inc
- GlaxoSmithKline Plc
- Guangzhou Bairui Biomedical Technology Co Ltd
- Guangzhou Doublle Bioproduct Inc
- Harbin Gloria Pharmaceuticals Co Ltd
- HRYZ (ShenZhen) Biotech Co
- Huabo Biopharm (Shanghai) Co Ltd
- Immix BioPharma Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Immunomic Therapeutics Inc
- Incyte Corp
- Inhibrx Inc
- Inmune Bio Inc
- Innovent Biologics Inc
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Joint Biosciences Ltd
- Karyopharm Therapeutics Inc
- Kuur Therapeutics Ltd
- Lion TCR Pte Ltd
- Merck & Co Inc
- Merck KGaA
- Molecular Targeting Technologies Inc
- Neonc Technologies Inc
- Novartis AG
- Ono Pharmaceutical Co Ltd
- Oxford Vacmedix UK Ltd
- Polaris Pharmaceuticals Inc
- Qilu Puget Sound Biotherapeutics Corp
- Rapa Therapeutics LLC
- RAPT Therapeutics Inc
- Rubius Therapeutics Inc
- Seven and Eight Biopharmaceuticals Corp
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai GeneChem Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Miracogen Inc
- Shenghe (China) Biopharmaceutical Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Soricimed Biopharma Inc
- Suzhou Zelgen Biopharmaceutical Co Ltd
- TCR Cure Biopharma Technology Co Ltd
- Tessa Therapeutics Ltd
- TOT Biopharm Co Ltd
- Transcenta Holding Ltd
- Vectorite Biomedical Inc
- Viracta Therapeutics Inc
- Xencor Inc
- Xiangxue Life Sciences
- Y-Biologics Inc
- Nasopharyngeal Cancer β Drug Profiles
- (curcumin + doxorubicin) β Drug Profile
- anlotinib hydrochloride β Drug Profile
- Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer β Drug Profile
- apatinib mesylate β Drug Profile
- APG-1387 β Drug Profile
- APL-502 β Drug Profile
- ARX-305 β Drug Profile
- ASTX-660 β Drug Profile
- ATA-190 β Drug Profile
- atezolizumab β Drug Profile
- avelumab β Drug Profile
- baltaleucel-T β Drug Profile
- bavunalimab β Drug Profile
- BDB-001 β Drug Profile
- bevacizumab β Drug Profile
- BG-001 β Drug Profile
- BG-002 β Drug Profile
- BGB-10188 β Drug Profile
- bintrafusp alfa β Drug Profile
- BMS-986207 β Drug Profile
- Cabometyx β Drug Profile
- cadonilimab β Drug Profile
- camrelizumab β Drug Profile
- Cellular Immunotherapy for EBV Associated Malignancies β Drug Profile
- Cellular Immunotherapy for EpsteinβBarr Virus Infections and Nasopharyngeal Cancer β Drug Profile
- Cellular Immunotherapy for Nasopharyngeal Cancer β Drug Profile
- Cellular Immunotherapy for Oncology β Drug Profile
- Cellular Immunotherapy to Target CD137L for Nasopharyngeal Cancer β Drug Profile
- COM-701 β Drug Profile
- dalpiciclib β Drug Profile
- DC-120 β Drug Profile
- DKY-709 β Drug Profile
- DN-1508052 β Drug Profile
- donafenib tosylate β Drug Profile
- durvalumab β Drug Profile
- durvalumab + tremelimumab β Drug Profile
- E-10B β Drug Profile
- EBViNT β Drug Profile
- EDS-01 β Drug Profile
- eltanexor β Drug Profile
- EMB-02 β Drug Profile
- EMB-09 β Drug Profile
- epacadostat β Drug Profile
- ficlatuzumab β Drug Profile
- FLX-475 β Drug Profile
- GB-3015 β Drug Profile
- GB-5008 β Drug Profile
- gedeptin β Drug Profile
- Gene Therapy for EpsteinβBarr Virus Associated Nasopharyngeal Cancer β Drug Profile
- Gene Therapy for Nasopharyngeal Cancer β Drug Profile
- Gene Therapy for Oncology β Drug Profile
- Gene Therapy to Target EPCAM for Oncology β Drug Profile
- Gene Therapy to Target FAP for Nasopharyngeal Cancer and Solid Tumor β Drug Profile
- Gene Therapy to Target Latent Membrane Protein-2 for Epstein-Barr Virus Associated Cancer β Drug Profile
- Gene Therapy to Target LMP1 for Epstein-Barr Virus Associated Nasopharyngeal Cancer β Drug Profile
- Gene Therapy to Target LMP2 for EBV Associated Nasopharyngeal Carcinoma β Drug Profile
- Gene Therapy to Target LMP2 for Nasopharyngeal Carcinoma β Drug Profile
- Gene Therapy To Target Nectin4 and NKG2DL for Nasopharyngeal Cancer and Solid Tumor β Drug Profile
- geptanolimab β Drug Profile
- GF-101 β Drug Profile
- GNSTEBV-001 β Drug Profile
- GR-1405 β Drug Profile
- HB-0021 β Drug Profile
- IBC-0966 β Drug Profile
- IBI-310 β Drug Profile
- IBI-323 β Drug Profile
- IMM-01 β Drug Profile
- INBRX-106 β Drug Profile
- INKmune β Drug Profile
- ipilimumab + nivolumab β Drug Profile
- ITI-4000 β Drug Profile
- izuralimab β Drug Profile
- JS-003 β Drug Profile
- JS-004 β Drug Profile
- KLA-167 β Drug Profile
- KN-046 β Drug Profile
- L-100s β Drug Profile
- L-200s β Drug Profile
- L-300s β Drug Profile
- lucitanib β Drug Profile
- LY-3434172 β Drug Profile
- MAK-683 β Drug Profile
- MASCT β Drug Profile
- mipasetamab uzoptirine β Drug Profile
- Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma β Drug Profile
- Monoclonal Antibody to Target BARF-1 for Epstein-Barr Virus Infections and Oncology β Drug Profile
- MRG-003 β Drug Profile
- MVA vaccine β Drug Profile
- nanatinostat β Drug Profile
- NEO-212 β Drug Profile
- nimotuzumab biosimilar β Drug Profile
- niraparib β Drug Profile
- nivolumab β Drug Profile
- NJH-395 β Drug Profile
- OVM-400 β Drug Profile
- OVV-01 β Drug Profile
- pegargiminase β Drug Profile
- pembrolizumab β Drug Profile
- penpulimab β Drug Profile
- Peptide to Inhibit EBNA1 And LMP1 for Nasopharyngeal Cancer β Drug Profile
- PSB-205 β Drug Profile
- RAPA-201 β Drug Profile
- rovaleucel β Drug Profile
- RTX-321 β Drug Profile
- SHR-1701 β Drug Profile
- SIM-325 β Drug Profile
- sintilimab β Drug Profile
- Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer β Drug Profile
- SORC-13 β Drug Profile
- spartalizumab β Drug Profile
- Synthetic Peptide to Target Somatostatin Receptor for Oncology β Drug Profile
- tabelecleucel β Drug Profile
- TAEST-16007 β Drug Profile
- tipifarnib β Drug Profile
- tislelizumab β Drug Profile
- toripalimab β Drug Profile
- TQB-2858 β Drug Profile
- TST-005 β Drug Profile
- TT-11X β Drug Profile
- Vaccine for EBV Associated Nasopharyngeal Cancer and Hodgkin Lymphoma β Drug Profile
- VK-2019 β Drug Profile
- vudalimab β Drug Profile
- Xgeva β Drug Profile
- YBL-006 β Drug Profile
- YTE-001 β Drug Profile
- zimberelimab β Drug Profile
- Nasopharyngeal Cancer β Dormant Projects
- Nasopharyngeal Cancer β Discontinued Products
- Nasopharyngeal Cancer β Product Development Milestones
- Featured News & Press Releases
- Apr 19, 2022: BeiGene presents updated results from phase 3 RATIONALE-309 Trial of PD-1 inhibitor Tislelizumab in first-line RM-NPC in Virtual ASCO Plenary Series
- Apr 08, 2022: Junshi Biosciences and Coherus present results of phase 3 study of toripalimab in first line treatment of recurrent or metastatic nasopharyngeal carcinoma at 2022 AACR Annual Meeting
- Mar 07, 2022: Voluntary announcement β JS001sc injection received the clinical trial approval
- Dec 10, 2021: BeiGene presents results from phase 3 trial of Tislelizumab in nasopharyngeal cancer at ESMO Immuno-Oncology Congress 2021
- Dec 03, 2021: Junshi Biosciences announces two additional indications for toripalimab included in Chinaβs National Reimbursement Drug List
- Dec 02, 2021: BeiGene to present new clinical data on Tislelizumab at ESMO IO Congress 2021
- Nov 29, 2021: Junshi Biosciences announces approval of supplemental new drug application by NMPA for Toripalimab in combination with Cisplatin and Gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma
- Nov 20, 2021: Sichuan Kelun Pharmaceutical Co : Announcement on the acceptance of the listing application for PD-L1 new drug Tetlizumab injection by NMPA
- Nov 01, 2021: Coherus and Junshi Biosciences announce FDA acceptance of BLA filing for toripalimab for treatment of nasopharyngeal carcinoma
- Oct 31, 2021: Shanghai Junshi Bioscience Co: Voluntary announcement βthe FDA accepted biologics license application of Toripalimab for treatment of nasopharyngeal carcinoma
- Oct 06, 2021: Viracta Therapeutics initiates phase 1b/2 trial in Epstein-Barr Virus-Positive (EBV+) solid tumors
- Sep 20, 2021: Pembrolizumab does not prolong overall survival compared to chemotherapy in platinum-pretreated recurrent or metastatic nasopharyngeal carcinoma
- Sep 15, 2021: Coherus and Junshi Biosciences announce results from phase 3 study of toripalimab published in September Issue of Nature Medicine
- Sep 01, 2021: Coherus and Junshi Biosciences announce completion of rolling BLA submission to U.S. FDA for toripalimab for the treatment of nasopharyngeal carcinoma
- Aug 22, 2021: BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in nasopharyngeal cancer
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Nasopharyngeal Cancer, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Products under Development by Companies, 2022
- Table 8: Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022 (Contd..2)
- Table 10: Products under Development by Companies, 2022 (Contd..3)
- Table 11: Products under Development by Companies, 2022 (Contd..4)
- Table 12: Products under Development by Companies, 2022 (Contd..5)
- Table 13: Products under Development by Companies, 2022 (Contd..6)
- Table 14: Products under Development by Universities/Institutes, 2022
- Table 15: Number of Products by Stage and Target, 2022
- Table 16: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 17: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 18: Number of Products by Stage and Target, 2022 (Contd..3)
- Table 19: Number of Products by Stage and Mechanism of Action, 2022
- Table 20: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 21: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 22: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
- Table 23: Number of Products by Stage and Route of Administration, 2022
- Table 24: Number of Products by Stage and Molecule Type, 2022
- Table 25: Nasopharyngeal Cancer β Pipeline by ADC Therapeutics SA, 2022
- Table 26: Nasopharyngeal Cancer β Pipeline by Advenchen Laboratories LLC, 2022
- Table 27: Nasopharyngeal Cancer β Pipeline by Akeso Inc, 2022
- Table 28: Nasopharyngeal Cancer β Pipeline by Alphamab Oncology, 2022
- Table 29: Nasopharyngeal Cancer β Pipeline by Ambrx Biopharma Inc, 2022
- Table 30: Nasopharyngeal Cancer β Pipeline by Amgen Inc, 2022
- Table 31: Nasopharyngeal Cancer β Pipeline by Apollomics Inc, 2022
- Table 32: Nasopharyngeal Cancer β Pipeline by Ascentage Pharma Group International, 2022
- Table 33: Nasopharyngeal Cancer β Pipeline by Astex Pharmaceuticals Inc, 2022
- Table 34: Nasopharyngeal Cancer β Pipeline by AstraZeneca Plc, 2022
- Table 35: Nasopharyngeal Cancer β Pipeline by Atara Biotherapeutics Inc, 2022
- Table 36: Nasopharyngeal Cancer β Pipeline by AVEO Pharmaceuticals Inc, 2022
- Table 37: Nasopharyngeal Cancer β Pipeline by BeiGene Ltd, 2022
- Table 38: Nasopharyngeal Cancer β Pipeline by Biomics Biotechnologies Co Ltd, 2022
- Table 39: Nasopharyngeal Cancer β Pipeline by BioSyngen Pte Ltd, 2022
- Table 40: Nasopharyngeal Cancer β Pipeline by BP InnoMed Ltd, 2022
- Table 41: Nasopharyngeal Cancer β Pipeline by Bristol-Myers Squibb Co, 2022
- Table 42: Nasopharyngeal Cancer β Pipeline by Chengdu Wonho Biology Engineering Co Ltd, 2022
- Table 43: Nasopharyngeal Cancer β Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
- Table 44: Nasopharyngeal Cancer β Pipeline by China Immunotech Co Ltd, 2022
- Table 45: Nasopharyngeal Cancer β Pipeline by Compugen Ltd, 2022
- Table 46: Nasopharyngeal Cancer β Pipeline by Eli Lilly and Co, 2022
- Table 47: Nasopharyngeal Cancer β Pipeline by EpimAb Biotherapeutics Inc, 2022
- Table 48: Nasopharyngeal Cancer β Pipeline by Eutilex Co Ltd, 2022
- Table 49: Nasopharyngeal Cancer β Pipeline by Exelixis Inc, 2022
- Table 50: Nasopharyngeal Cancer β Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 51: Nasopharyngeal Cancer β Pipeline by Geneius Biotechnology Inc, 2022
- Table 52: Nasopharyngeal Cancer β Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2022
- Table 53: Nasopharyngeal Cancer β Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
- Table 54: Nasopharyngeal Cancer β Pipeline by GeoVax Labs Inc, 2022
- Table 55: Nasopharyngeal Cancer β Pipeline by GlaxoSmithKline Plc, 2022
- Table 56: Nasopharyngeal Cancer β Pipeline by Guangzhou Bairui Biomedical Technology Co Ltd, 2022
- Table 57: Nasopharyngeal Cancer β Pipeline by Guangzhou Doublle Bioproduct Inc, 2022
- Table 58: Nasopharyngeal Cancer β Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
- Table 59: Nasopharyngeal Cancer β Pipeline by HRYZ (ShenZhen) Biotech Co, 2022
- Table 60: Nasopharyngeal Cancer β Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
- Table 61: Nasopharyngeal Cancer β Pipeline by Immix BioPharma Inc, 2022
- Table 62: Nasopharyngeal Cancer β Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
- Table 63: Nasopharyngeal Cancer β Pipeline by Immunomic Therapeutics Inc, 2022
- Table 64: Nasopharyngeal Cancer β Pipeline by Incyte Corp, 2022
- Table 65: Nasopharyngeal Cancer β Pipeline by Inhibrx Inc, 2022
- Table 66: Nasopharyngeal Cancer β Pipeline by Inmune Bio Inc, 2022
- Table 67: Nasopharyngeal Cancer β Pipeline by Innovent Biologics Inc, 2022
- Table 68: Nasopharyngeal Cancer β Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 69: Nasopharyngeal Cancer β Pipeline by Johnson & Johnson, 2022
- Table 70: Nasopharyngeal Cancer β Pipeline by Joint Biosciences Ltd, 2022
- Table 71: Nasopharyngeal Cancer β Pipeline by Karyopharm Therapeutics Inc, 2022
- Table 72: Nasopharyngeal Cancer β Pipeline by Kuur Therapeutics Ltd, 2022
- Table 73: Nasopharyngeal Cancer β Pipeline by Lion TCR Pte Ltd, 2022
- Table 74: Nasopharyngeal Cancer β Pipeline by Merck & Co Inc, 2022
- Table 75: Nasopharyngeal Cancer β Pipeline by Merck KGaA, 2022
- Table 76: Nasopharyngeal Cancer β Pipeline by Molecular Targeting Technologies Inc, 2022
- Table 77: Nasopharyngeal Cancer β Pipeline by Neonc Technologies Inc, 2022
- Table 78: Nasopharyngeal Cancer β Pipeline by Novartis AG, 2022
- Table 79: Nasopharyngeal Cancer β Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Table 80: Nasopharyngeal Cancer β Pipeline by Oxford Vacmedix UK Ltd, 2022
- Table 81: Nasopharyngeal Cancer β Pipeline by Polaris Pharmaceuticals Inc, 2022
- Table 82: Nasopharyngeal Cancer β Pipeline by Qilu Puget Sound Biotherapeutics Corp, 2022
- Table 83: Nasopharyngeal Cancer β Pipeline by Rapa Therapeutics LLC, 2022
- Table 84: Nasopharyngeal Cancer β Pipeline by RAPT Therapeutics Inc, 2022
- Table 85: Nasopharyngeal Cancer β Pipeline by Rubius Therapeutics Inc, 2022
- Table 86: Nasopharyngeal Cancer β Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022
- Table 87: Nasopharyngeal Cancer β Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
- Table 88: Nasopharyngeal Cancer β Pipeline by Shanghai GeneChem Co Ltd, 2022
- Table 89: Nasopharyngeal Cancer β Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 90: Nasopharyngeal Cancer β Pipeline by Shanghai Miracogen Inc, 2022
- Table 91: Nasopharyngeal Cancer β Pipeline by Shenghe (China) Biopharmaceutical Co Ltd, 2022
- Table 92: Nasopharyngeal Cancer β Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
- Table 93: Nasopharyngeal Cancer β Pipeline by Soricimed Biopharma Inc, 2022
- Table 94: Nasopharyngeal Cancer β Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
- Table 95: Nasopharyngeal Cancer β Pipeline by TCR Cure Biopharma Technology Co Ltd, 2022
- Table 96: Nasopharyngeal Cancer β Pipeline by Tessa Therapeutics Ltd, 2022
- Table 97: Nasopharyngeal Cancer β Pipeline by TOT Biopharm Co Ltd, 2022
- Table 98: Nasopharyngeal Cancer β Pipeline by Transcenta Holding Ltd, 2022
- Table 99: Nasopharyngeal Cancer β Pipeline by Vectorite Biomedical Inc, 2022
- Table 100: Nasopharyngeal Cancer β Pipeline by Viracta Therapeutics Inc, 2022
- Table 101: Nasopharyngeal Cancer β Pipeline by Xencor Inc, 2022
- Table 102: Nasopharyngeal Cancer β Pipeline by Xiangxue Life Sciences, 2022
- Table 103: Nasopharyngeal Cancer β Pipeline by Y-Biologics Inc, 2022
- Table 104: Nasopharyngeal Cancer β Dormant Projects, 2022
- Table 105: Nasopharyngeal Cancer β Dormant Projects, 2022 (Contd..1)
- Table 106: Nasopharyngeal Cancer β Dormant Projects, 2022 (Contd..2)
- Table 107: Nasopharyngeal Cancer β Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Nasopharyngeal Cancer, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.